For more than a decade this newsletter has tried to keep you informed with the latest literature, mainly regarding interventional therapy of intracranial aneurysms. International experts review recent articles on this topic and provide you not only with summaries of the results, but also with their personal opinions about the research. Obviously the readers like this format, currently 300 colleagues receive the newsletter electronically and the number is still increasing.

With this edition of the newsletter a minimal change has occurred. From the beginning Boston Scientific has sponsored this newsletter and I am very grateful that the company supported this kind of independent scientific information. Now Stryker has taken over the neurointerventional business from Boston Scientific. Sometimes this leads to tsunami-like changes in companies. Obviously not in this acquistion and I am very happy that Stryker has agreed to continue with the newsletter. Part of this newsletter covers the first results of the MAPS™ Trial. My personal opinion is that this is one of the best ways to organize studies. Take notice of it! Warm regards, Michael Forsting

Decargar noticia completa